11:21 AM EST - Oncolytics Biotech Inc : Announced clinical and translational findings supporting the development of pelareorep in second-line metastatic colorectal cancer, specifically in patients with KRAS-mutant, microsatellite-stable disease. This represents one of the most difficult-to-treat and least responsive subgroups within colorectal cancer. Oncolytics Biotech Inc
shares N.ONCY are trading up $0.06 at $0.98.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=8894903721878016
